Parkinsonism after glycine-derivate exposure

Movement Disorders

Volumn 16, Issue 3, 2001, Pages 565-568

  Barbosa, Egberto R ^a   Leiros da Costa, Maria D ^a   Bacheschi, Luiz A ^a   Scaff, Milberto ^a   Leite, Claudia C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BENSERAZIDE PLUS LEVODOPA; BIPERIDEN; GLYPHOSATE; HERBICIDE;

ADULT; ARTICLE; ATTENTION; CASE REPORT; DRUG RESPONSE; GLOBUS PALLIDUS; HUMAN; MALE; MEMORY DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PRIORITY JOURNAL; SKIN DEFECT; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; BENSERAZIDE; DRUG THERAPY, COMBINATION; GLOBUS PALLIDUS; GLYCINE; HERBICIDES; HUMANS; LEVODOPA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; VIDEOTAPE RECORDING;

EID: 0035353738     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.1105     Document Type: Article

References (30)

1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
2. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for clinician. J Psychiatr Res 1975;12:89-198.
3. Ferraz HB, Bertolucci PHF, Pereira JS, Camargo Lima JG, Andrade LAF. Chronic exposure to the fungicide maneb and signs of CNS manganese intoxication. Neurology 1988;38:550-553.
4. Marchiori PE, Barbosa ER, Scaff M, et al. Síndrome parkinsoniana em intoxicação por inseticidas organofosforados. Neurobiologia 1984,47:273-280.
5. Cavallazzi LO, Vieira P. Parkinsonismo agudo após exposição a herbicidas: relato de caso. Dendrito 1999;5:43-44.
6. Langston JW, Ballard P, Tetrud J, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
7. Ramsay RR, Youngster SK, Nicklas WJ, et al. Structural dependence of the inhibition of mitochondrial respiration and a NADH oxidase by MPP+ analogs and their energised accumulation by mitochondria. Proc Natl Acad Sci USA 1989;86:9168-9172.
8. Youngster SK, Gluck MR, Heikkila RE, Nicklas WJ. 4-Alkylated analogs of MPP+ are potent inhibitors of mitochondrial respiration. Biochem Biophys Res Commun 1990;169:758-764.
9. Frank DM, Arora PK, Blumer JL, Sayre LM. Model study on the bioreduction of Paraquat, MPP+, and analogs. Evidence against a 'redox cycling' mechanism in MPTP neurotoxicity. Biochem Byophys Res Commun 1987;147:1095-1104.
10. Li S, Schoenberg BS, Wang C, et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 1985;42:655-657.
11. Schoenberg BS, Osuntokun BO, Adeuja AOG, et al. Comparison of the prevalence of Parkinson's disease in black population in the rural United States and in rural Nigeria: door-to-door community studies. Neurology 1988;38:645-646.
12. Ashok PP, Radhakrishan K, Sridharam R, Mousa ME. Epidemiology of Parkinson's disease in Benghasi, North-East Libya. Clin Neurol Neurosurg 1986; 88:109-113.
13. Rajput AH, Oxfford KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984;16:278-282.
14. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississipi. Neurology 1985;35:841-845.
15. Mutch WJ, Dingwall- Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's disease in a Scottsh city. BMJ 1986;292:534-536.
16. Rajput AH, Uitti RJ, Stern W, et al. Geography, drinking water, chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci 1987;14:414-418.
17. Golbe LI, Farrel TM; Davis PH. Follow-up study of early life protective and risk factors in PD. Mov Disord 1990;5:66-70.
18. Semchuck KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 1992; 42:1328-1335.
19. Koller W, Vetere-Overfield B, Gray C, et al. Environmental risk factors in Parkinson s disease. Neurology 1990;40:1218-1221.
20. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996;46:1275-1284.
21. Liou HH, Tsai MC, Chen CJ, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997;48:1583-1588.
22. Caparros-Lefebvre D, Elbaz A, and the Caribbean Parkinsonism Study Group. Lancet 1999;354:281-286.
23. Mizuno Y, Shimoda-Matsubayashi S, Matsumine H, et al. Genetic and environmental factors in the pathogenesis of Parkinson's disease. Adv Neurol 1999; 80:171-179.
24. Hammond BG, Vicini JL, Hartnell GF, Naylor MW, Knight CD, Robinson EH, Fuchs RL, Padgette SR. The feeding value of soybeans fed to rats, chickens, catfish and dairy cattle is not altered by genetic incorporation of glyphosate tolerance. J Nutr 1996;126: 717-727.
25. Newell DW, Barth A, Ricciardi TN, Malouf AT. Glycine causes increased excitability and neurotoxicity by activation of NMDA receptors in the hippocampus. Exp Neurol 1997;145:235-244.
26. Kanthasamy AG, Kanthasamy A, Matsumoto RR, Vu TQ, Truong DD. Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (R)-HA-966 in an experimental model of Parkinson's disease. Brain Res 1997;759:1-8.
27. Dannhardt G; Kohl BK. The glycine site on the NMDA receptor: structure-activity relationship and possible therapeutic implications. Curr Med Chem 1998; 5:253-263.
28. Kandell ER. Synaptic Interconnection. In: Kandell ER, Schwartz JH, Jessell TM, editors. Essentials of neural science and behavior. New York: Appleton & Lange; 1995. p 179-198.
29. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987;325:529-531.
30. Karcz Kubicha M, Lorenz B, Danysz W. Glycine B antagonists and partial agonists in rodent models of Parkinson's disease, comparison with uncompetitive N-methly-D- aspartate receptor antagonist. Neuropharmacology 1999;32;101-119.